Alerts will be sent to your verified email
Verify EmailPANACEABIO
Panacea Biotec
|
Novartis
|
Indoco Remedies
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
6.0 . | n/a | 57.0 . |
R&D as a % of Total Sales
|
5.51 % | n/a | 6.0 % |
Financials
|
|||
5 yr Average ROE
|
17.16 % | 8.0 % | 11.09 % |
5yr average Equity Multiplier
|
1.61 | 2.72 | 1.79 |
5yr Average Asset Turnover Ratio
|
0.4 | 0.18 | 0.92 |
5yr Avg Net Profit Margin
|
19.26 % | 17.12 % | 6.73 % |
Price to Book
|
2.94 | 3.04 | 2.79 |
P/E
|
0.0 | 23.24 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-102.87 Days | -23.33 Days | 53.79 Days |
Inventory Days
|
109.97 Days | 44.27 Days | 66.59 Days |
Days Receivable
|
37.7 Days | 38.18 Days | 76.04 Days |
Days Payable
|
294.14 Days | 124.28 Days | 121.65 Days |
5yr Average Interest Coverage Ratio
|
2.9 | 65.43 | 7.97 |
5yr Avg ROCE
|
-1.68 % | 5.91 % | 15.12 % |
5yr Avg Operating Profit Margin
|
-1.99 % | 15.15 % | 15.97 % |
5 yr average Debt to Equity
|
0.05 | 0.0 | 0.38 |
5yr CAGR Net Profit
|
-64.03 % | 37.01 % | 32.49 % |
5yr Average Return on Assets
|
6.95 % | 3.13 % | 6.31 % |
Shareholdings
|
|||
Promoter Holding
|
72.48 % | 70.68 % | 58.9 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-1.11 % | 0.0 | 0.21 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 1.16 % |
Panacea Biotec
|
Novartis
|
Indoco Remedies
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Capex
|
Capex
|
-
|
-
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Brand Wise Break-Up
|
Brand Wise Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|